Rhode Islandmed spa & injectable regulations
What’s changing for med spas and injectors in Rhode Island — GLP-1 compounding, scope-of-practice, and enforcement — plus the federal FDA and Federal Register actions that apply in Rhode Island. Med Spa Radar monitors it all and tells you, in plain language, what changed and what to do.
Latest Rhode Island changes
- CRITICALLegiScan2025-06-30
RI H5351: Mandates cosmetic medical procedures be performed by a physician, PA, APRN, or delegated to a qualified non-physician, non-PA or non-APRN under the supervision of a physician, physician assistant, or advanced practice registered nurse.
New RI law tightens regulations for med spas and injectors.
- CRITICALLegiScan2025-06-30
RI S0976: Mandates cosmetic medical procedures be performed by a physician, PA, APRN, or delegated to a qualified non-physician, non-PA or non-APRN under the supervision of a physician, physician assistant, or advanced practice registered nurse.
New supervision rules impact med spa procedures in Rhode Island.
- MONITORLegiScan2024-05-22
RI H8296: Provides that the performance of cosmetic medical services is the practice of medicine and surgery.
Key changes for medical spas on cosmetic services oversight.
- MONITORLegiScan2024-03-22
RI S2870: Provides that the performance of cosmetic medical services is the practice of medicine and surgery.
Proposed bill could redefine cosmetic services under medical practices.
- MONITORLegiScan2024-03-01
RI H7820: Provides that licensed health care facilities be prohibited from using a patients photograph for any office use.
New RI bill impacts patient photo usage in med spas.
Federal changes that apply in Rhode Island
FDA and Federal Register actions are nationwide — they govern Rhode Island practices too.
- CRITICALFEDERALFDA Enforcement2025-09-10
FDA recall (Class II): Semaglutide, 2.5 mg/mL injection, 2 mL., Boothwyn Pharmacy
FDA recalls compounded GLP-1 product for being subpotent.
- CRITICALFEDERALFDA Enforcement2025-08-13
FDA recall (Class II): Semaglutide + Cyanocobalamin 2.67 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Steri…
FDA recalls compounded GLP-1 product; check your stock now!
- CRITICALFEDERALFDA Enforcement2026-01-07
FDA recall (Class II): Wegovy (semaglutide) Injection, 0.5 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880…
FDA recalls Wegovy; med spas must check supplies!
- CRITICALFEDERALFDA Enforcement2026-03-11
FDA recall (Class II): Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061,…
FDA recalls Semaglutide for sterility issues—act now!
- CRITICALFEDERALFDA Enforcement2026-01-07
FDA recall (Class II): Wegovy (semaglutide) Injection, 1 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880 B…
FDA recalls Wegovy due to safety concerns; med spas must act.
- CRITICALFEDERALFDA Enforcement2025-07-02
FDA recall (Class II): Semaglutide, 2.5 mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80…
FDA recalls GLP-1 product over sterility issues.
What we monitor in Rhode Island
- Rhode Island legislature — bills on injectables, GLP-1s & scope of practice
- Rhode Island Board of Nursing — injector scope & delegation
- Rhode Island Medical Board — physician supervision & ownership rules
- Rhode Island Board of Pharmacy — compounding & 503A/503B
- U.S. FDA — enforcement, warning letters, recalls, shortages
- Federal Register — new rules on compounding & aesthetics
Rhode Island med spa compliance — FAQ
- Where do Rhode Island med spa and injectable regulations come from?
- Rhode Island med spas and injectors are governed by a mix of state and federal authorities — the Rhode Island legislature, and the state's boards of nursing, medicine, and pharmacy, alongside federal bodies like the FDA and the Federal Register. Med Spa Radar monitors all of them for Rhode Island and flags what changed in plain language.
- Does the FDA's GLP-1 compounding guidance apply in Rhode Island?
- Yes — federal FDA actions on GLP-1 compounding (semaglutide, tirzepatide) apply nationwide, including in Rhode Island. We track those federal changes alongside any Rhode Island-specific rules so you see the full picture for your practice.
- How do I keep up with Rhode Island regulatory changes?
- Med Spa Radar sends a free weekly Brief on what changed across Rhode Island, the FDA, and the Federal Register. Members get the exact "what to do" for their states in real time. It's regulatory monitoring, not legal advice.
Never miss a Rhode Island change
Get the free weekly Brief on what changed across Rhode Island, the FDA, and the Federal Register. Members get the exact what-to-do, in real time, for their states.
Get the free Brief →← All states · Regulatory monitoring, not legal advice.